![CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19 CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19](https://mma.prnewswire.com/media/92552/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg?p=facebook)
CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19
CTI BioPharma Corp. Annuncia l'approvazione accelerata della FDA di VONJO (pacritinib) per il trattamento di pazienti adulti con mielofibrosi e trombocitopenia | MarketScreener
![Esautomotion – Pronta a un altro anno di crescita sfruttando i reshoring, rafforzando la struttura manageriale e spingendo sul M&A | Market Insight Esautomotion – Pronta a un altro anno di crescita sfruttando i reshoring, rafforzando la struttura manageriale e spingendo sul M&A | Market Insight](https://marketinsight.it/wp-content/uploads/2023/01/outlook-2.jpg)